Leerink Partners Issues Positive Forecast for Xeris Biopharma (NASDAQ:XERS) Stock Price

Xeris Biopharma (NASDAQ:XERS) had its price objective boosted by Leerink Partners from $5.00 to $6.00 in a research note released on Friday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

A number of other brokerages have also commented on XERS. Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday. Piper Sandler restated a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $5.92.

Xeris Biopharma Stock Down 1.1 %

Shares of Xeris Biopharma stock traded down $0.05 on Friday, hitting $4.20. 588,158 shares of the company traded hands, compared to its average volume of 1,907,529. The company has a market cap of $625.39 million, a PE ratio of -9.30 and a beta of 2.32. The company has a 50-day moving average price of $3.57 and a 200 day moving average price of $3.26. Xeris Biopharma has a 12-month low of $1.69 and a 12-month high of $4.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Mackenzie Financial Corp lifted its stake in shares of Xeris Biopharma by 446.0% during the fourth quarter. Mackenzie Financial Corp now owns 129,952 shares of the company’s stock worth $441,000 after buying an additional 106,153 shares during the period. Squarepoint Ops LLC raised its stake in Xeris Biopharma by 118.2% during the 4th quarter. Squarepoint Ops LLC now owns 40,769 shares of the company’s stock worth $138,000 after acquiring an additional 22,084 shares in the last quarter. Two Sigma Advisers LP acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth about $47,000. Stonepine Capital Management LLC acquired a new stake in Xeris Biopharma in the fourth quarter valued at about $618,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in Xeris Biopharma during the fourth quarter worth $79,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.